In the last three months, 10 analysts have published ratings on Integra Lifesciences IART, offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 1 | 3 | 1 | 5 |
| Last 30D | 0 | 0 | 0 | 0 | 1 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 2 |
| 3M Ago | 0 | 1 | 3 | 1 | 2 |
Analysts have recently evaluated Integra Lifesciences and provided 12-month price targets. The average target is $25.1, accompanied by a high estimate of $35.00 and a low estimate of $16.00. Experiencing a 7.41% decline, the current average is now lower than the previous average price target of $27.11.
Analyzing Analyst Ratings: A Detailed Breakdown
A comprehensive examination of how financial experts perceive Integra Lifesciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joanne Wuensch | Citigroup | Lowers | Sell | $16.00 | $20.00 |
| Ryan Zimmerman | BTIG | Lowers | Sell | $20.00 | $22.00 |
| Joanne Wuensch | Citigroup | Lowers | Sell | $20.00 | $23.00 |
| David Turkaly | JMP Securities | Lowers | Market Outperform | $35.00 | $40.00 |
| Richard Newitter | Truist Securities | Lowers | Hold | $26.00 | $32.00 |
| Joanne Wuensch | Citigroup | Lowers | Sell | $23.00 | $30.00 |
| Ryan Zimmerman | BTIG | Announces | Sell | $22.00 | - |
| Richard Newitter | Truist Securities | Raises | Hold | $32.00 | $25.00 |
| Drew Ranieri | Morgan Stanley | Raises | Underweight | $27.00 | $24.00 |
| Joanne Wuensch | Citigroup | Raises | Neutral | $30.00 | $28.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Integra Lifesciences. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Integra Lifesciences compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Integra Lifesciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Integra Lifesciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Integra Lifesciences analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Unveiling the Story Behind Integra Lifesciences
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
Integra Lifesciences: Delving into Financials
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Integra Lifesciences's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 9.68%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Integra Lifesciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -2.97%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Integra Lifesciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.79%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.3%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 1.31, Integra Lifesciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Basics of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
